라이브스코어 바카라사이트 Announces Q3 Results: Growth in Both Sales to 153.7 Billion Won, Operating Profit to 9.9 Billion Won

[by Lee, Young Sung] Huons Co., Ltd. has achieved growth in both sales and operating profit compared to the same period last year, due to the recovery of exports of injectable products to the US and increase in Contract Manufacturing Organization (CMO) for eye drops.

라이브스코어 바카라사이트 announced its preliminary earnings for the third quarter of this year on November 10, reporting consolidated sales of 153.7 billion won, operating profit of 9.9 billion won, and net profit of 8.2 billion won, reflecting year-on-year increase of 4.7%, 13.7%, and 13.3%, respectively.

Huons’ sustained growth in the third quarter was driven by exports of anesthetics, and expansion in Ethical Drug (ETC) and CMO business segments.

By business segment, the ETC business recorded 라이브스코어 바카라사이트 of 70 billion won (+5.1% YoY) in the third quarter. Especially, the 라이브스코어 바카라사이트 on main anesthetics product showed strong growth, 44% surge compared to the same period last year. Export 라이브스코어 바카라사이트 of injectable products has increased by 51% compared to the previous year, due to recovery of exports to the US, which had been sluggish last year.

Sales from the beauty and wellness segment recorded 35.3 billion won (-27.6% YoY). The sales from the health functional foods business was transferred to the subsidiary ‘Huons N’, as the business was separated and merged to the subsidiary in May. The beauty and wellness segment recorded 34.7 billion won in sales (+0.1% YoY) after excluding sales from the remaining health functional foods.

라이브스코어 바카라사이트 from the CMO segment recorded 19.9 billion won (+28.0% YoY). Increased operation of the eye drop production line at Plant 2 led to a 14% year-on-year increase in CMO 라이브스코어 바카라사이트 for eye drops. Likewise, CMO 라이브스코어 바카라사이트 for injectables and other pharmaceuticals rose 37% compared to the same period last year.

Subsidiary companies also showed solid performances. The health functional foods subsidiary, ‘Huons N’, completed transfer of sales from the spin-off and merger and continued its sales growth trend from last quarter, recording 19.4 billion won (+40.8% YoY). HuonsLifeSciences, which had posted losses until last year, maintained both sales growth compared to the same period last year and a turnaround to profitability in the third quarter.

라이브스코어 바카라사이트 recently obtained GMP certification for the new injectable production line at Plant 2. The company plans to operate the Plant 2 within this year to boost future sales and profitability.

Huons CEO Song Soo-young said, “Huons was able to sustain its upward trend in the third quarter driven by strong growth in pharmaceutical exports and CMO sales, as well as improved subsidiaries’ performances. Huons will focus on maximizing capacity in Plant 2 and, with the recent introduction of new R&D pipeline, strengthening its long-term growth momentum.”

Moreover, Huons announced the issuance of exchangeable bonds based on treasury shares for existing loan repayment. Also, Huons has decided to invest in its subsidiary specialized in health functional foods, 'Huons N', for the acquisition of a manufacturer equipped with production facilities. Due to rising export volumes of health functional foods, Huons N’s spout production line has been operating beyond its maximum capacity. While continued growth in exports is expected, the company has decided that there was an imminent need to scale up the capacity.

On the same day, the board of directors of Huons has decided on the third-quarter cash dividend of 570 won per share and set the record date for the dividend as November 25. This marks Huons’ first quarterly dividend payment. Furthermore, the company transferred its capital surplus to retained earnings in order to provide a source of funds for dividends. Structured as a tax-advantaged return, distribution by reduction of capital, this dividend allows shareholders to receive a non-taxable benefit. At the previous semi-annual dividend, the per-share dividend was slightly reduced compared to the previous year, but with this additional dividend in the third quarter, the company has maintained its policy of raising dividends by 0-30% year-over-year.